Two newer drugs for multiple myeloma failed to improve on a commonly used treatment regimen in separate late-stage studies of newly diagnosed patients, showcasing the difficulty in improving on Celgene's top-seller Revlimid in early disease settings.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,